Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Sean M. McBride(Memorial Sloan Kettering Cancer Center), Nancy Y. Lee(Memorial Sloan Kettering Cancer Center), Robert J. Young(Memorial Sloan Kettering Cancer Center), Daniel C. McFarland(Memorial Sloan Kettering Cancer Center), Nadeem Riaz(Memorial Sloan Kettering Cancer Center), Jahan Aghalar(Memorial Sloan Kettering Cancer Center), Alan L. Ho(Memorial Sloan Kettering Cancer Center), D. Spielsinger(Memorial Sloan Kettering Cancer Center), Juliana Eng(Memorial Sloan Kettering Cancer Center), Lara Dunn(Memorial Sloan Kettering Cancer Center), Robert A. Lefkowitz(Memorial Sloan Kettering Cancer Center), Eric J. Sherman, Wanqing Iris Zhi(NYU Langone Health), C. Jillian Tsai(Princess Margaret Cancer Centre), Jessica Flynn(Memorial Sloan Kettering Cancer Center), Zhigang Zhang(Memorial Sloan Kettering Cancer Center), Shrujal S. Baxi(Cambridge Health Alliance), Loren S. Michel(Memorial Sloan Kettering Cancer Center), David G. Pfister(Memorial Sloan Kettering Cancer Center)
Cited by 393
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
|Journal of Clinical Oncology|2003|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k